Take2 Health Collaborating with CXA to Provide Innovative Employee Benefits
Starting from November 2020, the Take2 Prophecy™ Test for Nasopharyngeal Cancer and other health assessment services officially joined the CXA’s wellness provider network, providing the innovative medical solution to Hong Kong users.
Established in 2013, CXA Group has gradually become Asia’s largest and most widely adopted employee benefits platform. Its clients include world-renowned brands Starbucks, L'Oréal Group and so on. Currently, eligible employees could redeem the complimentary test with their welfare credits through the platform. Through the collaboration, Take2 Health and CXA jointly create a healthier and stronger team of talents for the business, and set the basis to encourage the public to include early cancer detection test as part of medical check-ups.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
